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Esophageal adenocarcinoma (EAC) incidence is increasing while 5-year survival rates remain
less than 15%. A lack of experimental models has hampered progress. We have generated
clinically annotated EAC organoid cultures that recapitulate the morphology, genomic, and
transcriptomic landscape of the primary tumor including point mutations, copy number
alterations, and mutational signatures. Karyotyping of organoid cultures has conﬁrmed
polyclonality reﬂecting the clonal architecture of the primary tumor. Furthermore, subclones
underwent clonal selection associated with driver gene status. Medium throughput drug
sensitivity testing demonstrates the potential of targeting receptor tyrosine kinases and
downstream mediators. EAC organoid cultures provide a pre-clinical tool for studies of clonal
evolution and precision therapeutics.
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Esophageal cancer is the eighth most common cancer glob-ally with signiﬁcant geographical variation in incidence1.There are two main histological subtypes, esophageal
squamous cell carcinoma (ESCC) and esophageal adenocarci-
noma (EAC), the latter has become the dominant subtype in
western countries over the past 30 years with a marked increase
in tumors occurring around the gastro-esophageal junction.
Gastroesophageal reﬂux is the best documented risk factor for
adenocarcinoma which can gradually evolve from the pre-
malignant condition Barrett’s esophagus2. EAC typically pre-
sents de novo, at an advanced stage, and has a poor overall
patient survival rates with <15% surviving more than 5 years.
With improved multimodality staging methods involving PET-
CT and endoscopic ultrasound, there is now a more stringent
selection for those patients being treated on a curative pathway.
Curative therapy, offered to approximately 55% of patients3,
generally involves neoadjuvant oncological therapy followed by
surgery. The basic regime is consistent while there are regional
variations in the chemotherapy regime and whether or not
radiotherapy is given; however, the results are consistent with a 5-
year survival rate of around 40% in clinical trials4,5. Targeted
therapy has lagged behind that of other cancers in view of the
disappointing trial data for receptor tyrosine kinases (RTKs) in
particular. At present, inhibitors of HER2 and VEGFR2 are
the only licensed drugs by the FDA for this disease, and they
are used as second line therapy for metastatic disease6,7. The
major obstacles for introducing new therapy approaches have
been a lack of understanding of the molecular genetic drivers of
EAC, increasing evidence for a high degree of intra- and inter-
tumor heterogeneity, and a lack of physiological model systems
for testing hypotheses including those related to clonal evolution
and new therapies.
Recent sequencing studies (exome and whole genome) have
shown that EAC is a cancer with a high mutation burden8, a
preponderance of copy number alterations and large-scale chro-
mosomal rearrangements, and the lack of clear recurrent driver
genes apart from TP539–12. Our recent study based on whole
genome sequencing (WGS) data for over 100 cases highlighted:
genomic catastrophes (such as chromothripsis and kataegis) in
around 30% of cases; almost ubiquitous co-ampliﬁcation of RTK
and disruption of RTK downstream targets; and occurrence of six
mutational signatures which provide the potential for patients to
be classiﬁed according to their dominant signature for therapy
decisions13.
One bottleneck for esophageal cancer research is a lack of
model systems reﬂecting the primary disease with which to study
pathogenesis and sensitivity to therapy14. A handful of two-
dimensional (2D) cell lines remain the most common in vitro
research model and unfortunately most of these lines do not have
genomic characterization of the primary from which they were
derived and no germline data exist in order to ﬁlter out the
inherited SNPs15. Although the mutational proﬁle of these lines
does recapitulate EAC to some extent, the mutational signatures
are not representative following in vitro culture over multiple
passages15,16. Mouse models have been challenging since there is
no clear genetic driver akin to APC in colon or KRAS in pancreatic
cancer. Genetically engineered mouse models of Barrett’s have
been developed by depleting p63 or overexpressing IL-1β; how-
ever, the mice in the former model do not survive into maturity,
and EAC tumors were found in less than 20% mice in the latter
model17,18. Physiological reﬂux models have proven technically
challenging to achieve in mice due to anatomical differences and
the high mortality associated with surgical reﬂux14,19. Hence,
there is a high demand from the research community to develop
a bank of patient-derived in vitro models that accurately mirror
the molecular heterogeneity of clinical EAC.
Advances in the understanding of primary cell niche factors
and regulation of signaling pathways to maintain long-term,
three-dimensional (3D) ex vivo culture models have provided
the breakthrough required to generate primary models from
multiple human organs including the GI tract20–22. The organoid
model system has the capability to overcome limitations of
the existing esophageal models by virtue of its stable culture
characteristics, ﬂexible manipulation, and faithful recapitulation
of the physiological properties of the primary tissue including
tissue heterogeneity. Organoid cultures have recently been
exploited to study stem cell biology, genomics, disease patho-
genesis, and cancer therapy23. Some initial investigation was
made to generate organoids from Barrett’s esophagus. However,
only a small number of cultures were successful, they lack detailed
genomic characterization and they have not been made widely
available24.
The aims of this study are to: (1) Establish a reliable protocol
for generating primary EAC organoid cultures with a view to
developing a publicly available biobank; (2) Provide a thorough
phenotypic and molecular characterization of EAC organoid
cultures including karyotyping, genomic proﬁling, cell kinetics,
polarity, and clonality analysis with patient-matched tumor tis-
sues; (3) Evaluate the clonality of EAC organoid cultures and the
sub-clonal evolution over time; (4) Demonstrate the feasibility of
moderate throughput drug screening to identify new therapeutic
targets and precision medicine strategies.
Results
Establishment of EAC organoid cultures. Freshly resected EAC
tissue samples were collected for organoid derivation from eso-
phagectomy; one tissue sample per patient was utilized. Organoid
cultures were successfully established from 10 patients with an
overall efﬁciency of 31% (10 of 32 samples; Table 1), consistent
with reported rates for derivation from advanced cancers25. Nine
of 10 successfully derived cultures were passaged at least 25 times
and grew for over 6 months, while CAM298 stopped growing.
Histopathological assessment of the primary tumor of CAM298
found this to be the only tumor that was well-differentiated and
responsive to neoadjuvant chemotherapy (Table 1). The doubling
time of the different organoid cultures was variable, ranging from
18 to 30 hours. The culture conditions were optimized for
glandular epithelial cell growth21,22,24 and thus minimized com-
petitive growth from normal squamous epithelium. The majority
of organoid cultures (6 of 10) were derived from chemotherapy-
resistant donors (tumor regression grading (TRG) 4 or 5),
although 3 organoids were derived from patients who had not
received chemotherapy (Table 1). The primary reasons for culture
failure were lack of growth from culture initiation (n= 11 cul-
tures), infection (n= 5), ﬁbroblast overgrowth (n= 4), and
arrested growth (n= 2). Normal gastric tissue taken at esopha-
gectomy was successfully derived as a healthy glandular control
tissue. Unfortunately, cultures from pre-malignant Barrett’s eso-
phagus were unsuccessful.
Histological characterization of EAC organoid cultures. To
verify whether organoids faithfully recapitulated the tumor tissue,
we ﬁrst evaluated the expression of epithelial speciﬁc markers.
There were a range of Tumor and Lymph Node stages (T, N)
and 9 of the cultures showed moderate to poor differentiation
as expected from the clinical demographics of the disease
(Table 1). Immunohistochemical (IHC) staining was present for
pan-cytokeratin with absent vimentin expression conﬁrming an
epithelial origin for all organoids (Fig. 1a). Regarding p53 status,
8/10 were mutated, in keeping with the prevalence observed
in EAC patients. Wild-type p53 expression pattern was observed
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in CAM296 and CAM247, loss in CAM277 (TP53-c.414delC)
and CAM338 (TP53-c.574C>T (p.Gln192Ter)), and intense
nuclear staining in CAM292 (TP53-c.818G>A (p.Arg273His))
and AH298 (TP53-c.742C>T (p.Arg248Trp)) (Figs. 1a, 2a). In
contrast, normal gastric organoid cultures exhibited the mor-
phological characteristics of a normal glandular architecture
with wild-type p53 expression pattern (Supplementary Fig. 1a),
and wild-type mutational status conﬁrmed by targeted gene
sequencing (Supplementary Data 1).
Disrupted polarity in EAC organoid cultures. Disruption of cell
polarity is one of the hallmarks of cancer which is important for
tumor initiation and progression. To visualize cell polarity,
we evaluated the expression of F-actin and alpha 6 integrin to
mark the apical and basal membranes, respectively. EAC-
derived organoids had a disordered structure and developed
multiple mini-luminal structures from day 3 after seeding, with
some inter-patient variation in their degree of complexity and
the extent of disruption of polarity (Fig. 1b, Supplementary
Fig. 1b). We then examined the distribution of proliferative cells
within the organoids. In contrast to the organized proliferative
compartment conﬁned to the outer layer in other cancer types24,
the organoids derived from EAC had proliferative cells present
throughout the organoid cell mass, which is in agreement with
the diffuse Ki67 staining pattern observed in the primary tumors
(Fig. 1c, Supplementary Fig. 1c).
Genomic characterization of tumor-derived organoids. Whole-
genome sequencing was performed to deﬁne the genomic land-
scape of the derived esophageal organoids. The 10 organoids
harbored a heterogeneous set of cancer drivers affected by non-
synonymous point mutations or insertions/deletions (InDels),
some of which showed a variable pattern of alteration (Fig. 2a).
The main EAC drivers reported in the literature to date were
observed in this organoid panel and the mutations were
consistent between the tumor and the organoid (e.g., TP53,
CDKN2A, KCNQ3, PIK3CA)10,13. This consistency was also
observed using the larger cancer gene census from the COSMIC
database26 (Supplementary Fig. 2a). In general, we observed a
higher allele frequency of driver mutations in organoid cultures
compared with patient-matched tumors, which is likely to be
explained by the pure tumor cellularity in the organoids (Fig. 2a,
Supplementary Data 2). Beyond cancer drivers, most of the
single nucleotide variants (SNV) and InDels, nonsynonymous
or otherwise, were concordant between patient-matched tumor
and organoid (Fig. 2b).
Six mutational signatures were observed in the organoid cultures
in keeping with EAC tumors9,10,13. Generally, the contribution of
the dominant signature(s) was consistent between the tumor and
organoid culture (Fig. 2c). Furthermore, the cultures reﬂected the
inter-patient heterogeneity reported previously, with 3/10 organoids
belonging to the “mutagenic” subtype, 2/10 to the “DDR impaired”
subtype, and 5/10 to the “C>A/T dominant” subtype as per the
classiﬁcation proposed in Secrier & Li et al.13 (Fig. 2b, Supplemen-
tary Table 1, Supplementary Fig. 2b).
Large-scale structural alterations showed an even higher
degree of concordance than SNVs/InDels, with the overall
copy number proﬁles being largely preserved (Fig. 3a). This
consistency was observed for clinically relevant RTKs as well as
for other focal or larger genomic segments; for example,
ampliﬁcations on chromosome 12 in CAM277, CAM401, and
CAM296, or on chromosome 17 in CAM408, and chromosome
20 in CAM338 (Fig. 3d, Supplementary Fig. 2c). The patterns
of structural rearrangement clearly indicated a common genetic
background for each organoid and its respective tumor of origin
(Fig. 3b, c, d, Supplementary Fig. 2c). Chromothriptic events
on chromosome 16 in CAM296 and the p arm of chromosome
3 in CAM338 were maintained in the respective organoids
(Supplementary Fig. 2c).
Some differences between organoid cultures and patient-
matched tumors were observed. Additional large segment
ampliﬁcations were found in the organoid from CAM296,
considerably fewer rearrangements in CAM292, as well as loss
of ploidy in the CAM292 and CAM296 organoids compared to
the tumors. Further, the landscape of SNVs/InDels was more
variable than large-scale structural variants (Fig. 2b vs. Fig. 3c).
For example, CAM296 had a reduced proportion of shared
alterations with its matched tumor, but larger scale patterns
such as structural variants or mutational signature composition,
which are more likely to have an impact on tumor ﬁtness and
development, were generally well preserved.
Patient-speciﬁc gene expression is conserved in organoids.
Messenger RNA sequencing was performed to quantify pheno-
typic similarity between the organoid and the tumor EAC sam-
ples. Using the Euclidean distance between the overall gene
expression proﬁles, the hierarchical clustering (Supplementary
Fig. 3a) indicates that tumors, normal squamous esophagus and
organoid samples form separate clusters, with the tumor and
normal clusters being more similar to each other than to orga-
noids. This likely reﬂects the organoid culture environment and
the presence of heterogeneous cell types in the primary tumor
and normal tissue samples, which are absent from the organoid
culture. To identify sets of genes that capture the patient-speciﬁc
Table 1 Summary table of clinical characteristics of patient donors
ID Age Sex Stage Chemotherapy regimen TRG Differentiation
CAM298 58 M ypT1bN0M0 ECX 2 Well
CAM388 78 M ypT2N0M0 ECX 4 Moderate to poor
CAM247 67 M ypT2N2M0 ECX 4 Moderate
CAM292 66 F ypT3N1MX ECX 4 Moderate to poor
CAM296 72 M ypT3N3MX ECF 4 Moderate to poor
CAM338 51 F ypT3N1MX ECX 5 Moderate to poor
CAM401 77 F ypT4aN2M0 CF 5 Poor
CAM412 52 F cT1bN0M0 No chemotherapy No chemotherapy Poor
CAM277 80 F cT3N2M0 No chemotherapy No chemotherapy Poor
CAM408 60 M cT1aN0M0 No chemotherapy No chemotherapy Moderate
The tumor regression grade (TRG) was used to describe histopathological response to chemotherapy, whereby 1 indicates complete regression and 5 is deﬁned as no regressive changes. Patients are
ranked by TRG
The acronyms for the chemotherapy regimens are: ECX Epirubicin, Oxaliplatin, Capecitabine, ECF Epirubicin, Cisplatin, 5-Flourouracil, EOX Epirubicin, Oxaliplatin, Capecitabine, and CF Cisplatin,
Fluorouracil
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expression proﬁle of the tumors, gene signatures for each patient
were deﬁned based on a comparison of tumors and organoids
to matched adjacent squamous epithelium and a cross-patient
comparison performed (see Methods). The mean correlation
coefﬁcient for the pair-wise comparisons of each tumor sample to
each organoid was 0.58 (median= 0.57, range= 0.41–0.84),
indicating that the expression patterns of tumors and organoids
are well correlated (Fig. 4a). Further, for most patients, the
highest correlation coefﬁcients were achieved between pairs of
organoids and patient-matched tumors. CAM292 and CAM412
organoid samples failed to correlate highly with their counterpart
tumor samples, in keeping with the reduced number of shared
SNV’s and InDels between these organoid cultures and matched
tumors (Fig. 2b).
To elucidate which mutations were expressed, we quantiﬁed
the expression of SNVs identiﬁed from the WGS analysis and
known to be EAC driver genes (Fig. 4b, Supplementary Fig. 3b, c).
Genes with SNVs were classiﬁed into: not expressed, reference
allele expressed, or alternative allele expressed depending on
the number of reads at the SNV loci and the variant allele fraction
of the alternative allele (see Methods). Consistent with DNA
sequencing, there is a high concordance between the patient-
matched tumor and the organoid with respect to driver gene
mutations expressed at the mRNA level.
Retention of intra-tumor heterogeneity and clonal dynamics.
Given that intra-tumor heterogeneity is a feature of EAC and may
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Fig. 1 Tumor organoid cultures share histopathological features with patient-matched tissue and disruption of polarity. a Representative images of H&E,
and IHC of Vim (Vimentin), panCK (pan-cytokeratin), and p53 from primary tissue and patient-matched organoid (40× magniﬁcation used for organoid
models and 20× for tissues). Images are grouped by p53 expression pattern. Scale bar= 100 μM in primary tissue images and 50 μM in organoid images.
b Representative whole-mount immunostaining images of tumor-derived organoids at days 3, 7, 14, and 21 after seeding, with anti-phalloidin (selectively
stain F-actin, apical marker, Red), integrin α6 (basolateral marker, green), Edu (proliferation marker, pink), and Hoechst (nuclei, blue) as indicated. Scale
bar= 10 μM. c Representative images of IHC of Ki67 from primary tumor tissue. Scale bar= 100 μM
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impact tumor progression, patient response to therapy, and
the emergence of resistance, we asked whether the clonal hier-
archy and dynamics are inherited by the derived organoid cul-
tures. To address this question, we ﬁrst set out to collect direct
evidence of the existence of heterogeneity at a single cell level
in the organoid culture. Spectral karyotyping (SKY) analysis
of organoid cultures revealed that most cells were aneuploid, and
all cultures are mixed heterogeneous populations composed
of cells with a variety of changes in chromosomal number as
well as chromosomal rearrangements (Fig. 5a, e, Supplementary
Fig. 4a, b, f). The karyotype of CAM296 (Supplementary Fig. 4b),
while heterogeneous, is relatively stable while the karyotype of
CAM338 shows evidence of whole-genome duplication (Fig. 5e).
To investigate the clonal structure and dynamics of these
cultures, 4 organoid cultures were propagated and samples
collected for whole-genome sequencing at multiple passages
(up to 16 passages) over a period of approximately 6 months. The
organoid genomes were relatively stable with increasing passage
with a small increase (<25%) in the number of total mutations
and nonsynonymous variants over time, none of which affected
cancer drivers (Supplementary Fig. 5a). The proportion of the
genome containing ampliﬁcations, deletions, or loss of hetero-
zygosity (LOH) regions showed little change over time (Supple-
mentary Fig. 5b). Furthermore, the copy number proﬁle appeared
to stay stable between passages (Supplementary Fig. 5c).
To estimate the clone size and dynamics of somatic evolution,
we used a Bayesian Dirichelet process to estimate the subclonal
architecture at each time point based on the allele frequency of
somatic mutations present. This analysis conﬁrmed that the
organoid cultures were polyclonal, with representation of all
clones found in the matched-primary tumor tissue (Fig. 5b, c, d, f,
g, h, Supplementary Fig. 4c, d, e, g, h, i, Supplementary Table 2).
Some of these pre-existing subclones were minor in the tumor
due to the low cancer cell frequency such as clone 4 in CAM296,
and clones 2 and 3 in CAM277.
In line with clonal selection found on engraftment in several
PDX model studies27,28, the largest changes in subclonal
composition were observed at the point of derivation and in
the initial passages. In the 4 cultures tested, 2 models (CAM296
and CAM401) showed a rapid evolution then stasis, with minor
subclones of the primary tumor becoming almost clonal in
the ﬁrst few passages and remaining dominant throughout
propagation (Supplementary Fig. 5c, d, e, g, h, i). In contrast, the
clonal evolution of CAM277 and CAM388 was slower with
subclonal dynamics ongoing several months after derivation
(Fig. 5b, c, d, f, g, h). We also observed that subclones containing
somatic nonsynonymous or regulatory mutations in COSMIC
cancer driver genes were more likely to expand in culture. For
instance, in the trunk of CAM277 (clone 1), which contained
16715 somatic mutations including ALK and TP53, was fully
clonal in the primary tumor and remained clonal in organoid
cultures; branch clone (clone 2) and its subclone (clone 3)
expanded during organoid propagation. In particular, clone 2
containing somatic mutation of RNF213 (E3 ubiquitin-protein
ligase involving noncanonical WNT signaling pathway29), was
almost clonal by the most recent passage. Conversely, another
branch clone (clone 4), which was nearly clonal in the tumor and
lacked driver mutations, gradually decreased in dominance in
the derived organoids (Fig. 5c). Similarly, in CAM296, mutated
KRAS and BCL6 were found in subclone 4 which became
the dominate clone in culture (Supplementary Fig. 5d). Further
studies are required to interpret the signiﬁcance of driver genes
in clonal expansion. Interestingly, regardless of the dynamic
evolution of subclones within organoid cultures, the six
mutational signatures were extremely stable over time, particu-
larly with regard to the dominant mutational signature (Fig. 5d, h
and Supplementary Fig. 4e, i).
Drug sensitivity in EAC organoid cultures. We next evaluated
the applicability of EAC organoids grown as 3D cultures for
drug sensitivity testing. We tested their sensitivity to 24 anti-
cancer compounds using a 7-point half-log dilution series
(1000× concentration range), including eight FDA approved
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drugs and 10 preclinical molecularly targeted agents against
key targets and pathways implicated in EAC (listed in Supple-
mentary Data 3)22,30. There was a good positive correlation of
the area under the dose–response curve (AUC) values across
biological replicates (n= 2 or 3 replicates; Rs > 0.8) for the entire
dataset (Supplementary Fig. 6a). Compounds with overlapping
targets had similar activity across the panel of organoid cultures
(Rs= 0.92 for PI3K inhibitors, Rs= 0.69 for IGF1R inhibitors,
and Rs= 0.53 for EGFR inhibitors, n= 9 organoids) (Supple-
mentary Fig. 6b).
Despite on-going clonal evolution, drug responses of individual
organoid cultures were consistent over time when comparing
sensitivity following prolonged culturing of up to 1 year
(Rs ≥ 0.85) (Supplementary Fig. 6c, d). Furthermore, drug
sensitivity was similar whether organoid cultures were plated
for screening as single cells or already formed multi-cellular
organoids (Supplementary Fig. 6e).
Consistent with the heterogeneity of EAC, we observed a range
of compound sensitivities across the nine organoid cultures
(Fig. 6). CAM277 and CAM338 were resistant to the majority
of compounds tested, with all IC50 values being greater than
the maximum screening concentration (10 μM for the majority of
compounds). The organoids with a DDR-impaired signature
(CAM401 and CAM296) were sensitive to the greatest number
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(plotted based on inter-mutational distance), copy number changes, and structural variants in the genomes of tumor CAM277 and matched organoid
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of compounds. For the remaining ﬁve organoid cultures,
sensitivities could be identiﬁed to at least two targeted agents,
eliciting an IC50 below a drug concentration of 1 or 0.1 μM.
Whilst CAM296 and CAM247 were TP53 wild-type, only
CAM296 demonstrated sensitivity to the MDM2 inhibitor
Nutlin-3a (IC50 3.1 μM) while CAM247 failed to respond (IC50
16 μM). The mediator of resistance in CAM247 could not be
identiﬁed. However, the varying sensitivity of wild-type TP53
lines is not uncommon31. Unsupervised clustering analysis of the
cell viability following drug treatment revealed clustering of
the ERK inhibitor SCH772984 and the MEK1/2 inhibitor
Trametinib, as well clustering of the EGFR-family inhibitors
Afatanib and Sapatinib. Notable sensitivities observed were
the MEK1/2 inhibitor Trametinib (n= 6 of 9 organoids with
IC50 < 0.1 μM), and with the EGFR/ERBB2 inhibitor Afatinib
(n= 3 of 9 organoids with IC50 < 250 nM).
We additionally examined the sensitivity of eight organoid
cultures to standard EAC chemotherapy agents 5-ﬂuoruracil,
epirubicin, and cisplatin (Supplementary Fig. 7a, b). The only
patient in our panel who responded to chemotherapy (TRG 2)
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had a well-differentiated organoid which did not proliferate
sufﬁciently for drug testing (CAM298). Six of the organoid
cultures (CAM388, CAM296, CAM338, CAM412, CAM277,
CAM408) were insensitive to single and combination che-
motherapy drugs. Three of these organoid cultures derived from
chemo-treated patients (CAM388, CAM296, CAM338) who all
had a poor response to therapy (TRG 4 or 5). Two organoid
cultures showed some limited sensitivity (CAM247 and
CAM401). Overall, the lack of chemotherapy sensitivity for
most organoid cultures (6 of 8) was consistent with the poor
in vivo response to neo-adjuvant chemotherapy seen in this
disease (Table 1).
Discussion
Here we demonstrate that human EAC organoid cultures can
be generated from human tissue retrieved at surgical resection.
A panel of 10 organoid cultures was generated with a success
rate of 31%. Ninety percent of these were capable of long-
term growth (>6 months) in culture. Our analyses provide
insight into the clonality of organoid cultures and the dynamics
of tumor subclones over extended in vitro culturing. This
renewable resource enriches the in vitro cell models of EAC
and provides the research community with models that have
extensive clinical, cellular, and molecular data including germline
reference sequence.
The comprehensive characterization of the organoid cultures
conﬁrmed that they recapitulated the features of the primary
tumors from which they were derived in terms of histology,
cancer driver alterations, mutational/copy-number/large-scale
genomic rearrangement landscape, mutational signature sub-
types, as well as expression proﬁle. Nevertheless, we did observe
gene expression signatures and genetic alterations unique to
either the tumor or the organoid model for all of the cases.
Differences in gene expression are likely due to the distinctive
microenvironments between the primary tumor and the organoid
culture system. Differences in genetic alteration detection are
likely due to the heterogeneity of the tumor of origin causing
sampling bias and/or selection of subclones during organoid
derivation and propagation. Furthermore, mutations have a
higher variant allele fraction in organoid cultures making SNV
easier to detect compared to patient tissue (Fig. 2a, Supplemen-
tary data 2). For example, in CAM277, a one-nucleotide deletion
(Chr9:21972087) of CDKN2A was detected in 8 of 33 total
reads in the primary tumor; in contrast, it was found in 23 of
23 total reads in the derived organoid culture (Supplementary
Data 2). We therefore curated variants called inconsistently
between the organoid and the primary, but nevertheless, this
could lead to some discordant calls (Fig. 2a). Notably, additional
variants identiﬁed in organoid cultures do not result in the
acquisition of additional EAC speciﬁc cancer driver genes absent
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in the patient-matched tumor. The stability of organoid culture
was reﬂected by the lack of additional cancer driver mutations
emerging and consistent mutational signatures following long-
itudinal culturing.
SKY and clonality analysis conﬁrmed that the organoid cul-
tures contain multiple subclones and these are shared with the
patient-matched tumor. The initial derivation of an organoid
culture led to the greatest selection pressure on genetic subclones
found in the tumor, and consequently the contribution of each
subclone in a culture. Nonetheless, all clones observed in the
organoid cultures could be traced back to the original tumor.
Organoid heterogeneity was maintained during culturing over
several months for all organoids tested, although dynamic clonal
behavior was observed in some models whereas others cultures
were relatively stable. Our observation of ongoing clonal evolu-
tion in organoid cultures indicates that these models could
provide a facile in vitro experimental system to investigate
factors such as the stromal cells, niche-factors and inter-clonal
cooperation/competition, and ordering of driver mutations,
which could impact on clonal evolution during tumor growth
and response to therapy.
Drug sensitivity testing using in vitro cancer cell models, is
used extensively during drug development in academia and
industry. Consistent with studies in colon22, pancreas32, liver33,
and prostate34 cancers, our results conﬁrm the tractability of
using EAC organoids for testing drug sensitivity. A range of
sensitivities to compounds were observed across the panel of EAC
cultures, including differential sensitivity to EGFR and MEK
inhibitors. This is consistent with the highly heterogeneous nature
of EAC and underscores the challenge of developing effective
treatments. This study was designed to evaluate the feasibility
of drug testing in EAC organoids. A larger collection of EAC
models, such as those being generated by an international con-
sortium such as the Human Cancer Models Initiative, will
enable the robust association of drug response with molecular
markers, and further studies are required to evaluate the in vivo
relevance of the drug candidates identiﬁed here. Despite evidence
for dynamic clonal populations in some organoid cultures,
drug sensitivity proﬁles were generally stable when compared
after prolonged periods in culture, indicating that the dominant
determinant(s) of sensitivity to a drug are shared by the different
subclones. This does not exclude the possibility of rare cells in a
culture with differential drug sensitivity, and which can underpin
clinical resistance to some therapies.
In general, the organoid cultures were insensitive to standard
combinations of EAC chemotherapy agents consistent with
patient responses. Indeed, following tumor resection, there is
rarely sufﬁcient tumor material available for organoid derivation
from patients who respond well to therapy. In the two instances
where sensitivity to chemotherapy was observed, this may be due
to clonal selection during derivation (as observed for CAM401),
tumor evolution in the time between neo-adjuvant chemotherapy
and surgery (typically 3 months), the subjectivity of the TRG
classiﬁcation, and differences in the in vivo tumor environment.
In the future, these models could be used to test for response
to radiotherapy, especially since this is increasingly used as
standard therapy, and the inclusion of stromal and immune cells
could further expand the utility of these models.
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In summary, a panel of EAC organoids has been derived
with extensive clinical, genomic, and phenotypic characteriza-
tion. These models reﬂect the morphological, functional, and
genetic features of the tissue of origin and can now be used to
address clinical translational questions including tumor het-
erogeneity and evolution, as well as providing insights into drug
sensitivity.
Methods
Ethical approval and sample collection. The study was registered (UKCRNID
8880), approved by the Institutional Ethics Committees (REC 07/H0305/52 and 10/
H0305/1), and all participants gave written informed consent as part of the
OCCAMS (Oesophageal Clinical And Molecular Stratiﬁcation) consortium. Sam-
ples were obtained from surgical resection. Half of the collected tissue samples
from each of the patients were prepared for organoid derivation while the other
half were snap-frozen using liquid nitrogen and stored at −80 °C until used for
genomic proﬁling. Blood or normal squamous esophageal samples (sampled at
least 5 cm in distance from the tumor) were used as a germline reference. Hae-
matoxylin and Eosin stained frozen tissue sections were reviewed for tumor cel-
lularity by two pathologists independently. Tumor tissue samples only with ≥70%
cellularity (primary tumor tissues of CAM247 and CAM298 were lower than this
threshold, therefore only primary normal tissue samples were sequenced for
organoid genomic characterization) were selected for DNA and RNA extraction
using the AllPrep kit (Qiagen) as were normal squamous esophageal tissue sam-
ples. DNA was extracted from blood samples using the QIAamp DNA Blood Maxi
kit (Qiagen).
Tumor and normal gastric organoid derivation. Tumor samples underwent
multiple washes with PBS before being minced into small pieces using a scalpel and
incubated with collagenase II (1.5 mg/ml) for 1–2 h at 37 °C. Following incubation,
the mixture was ﬁltered through a 70-μM cell strainer to remove large undigested
fragments. The cell suspension was centrifuged at 300–400×g for 2 min. The cell
pellet was resuspended in PBS and centrifugation repeated. This procedure was
repeated twice to remove debris and collagenase.
The isolated cells were re-suspended in 7.5 mg/ml basement membrane matrix
(Cultrex BME RGF type 2 (BME-2), Amsbio) supplemented with complete media
and plated as 10–15 μl droplets in a 6-well plate. After allowing the BME-2 to
polymerize, complete media was added and the cells left at 37 °C.
Complete media: AdDMEM/F12 medium supplemented with HEPES (1×,
Invitrogen), Glutamax (1×, Invitrogen), penicillin/streptomycin (1×, Invitrogen),
B27 (1×, Invitrogen), Primocin (1 mg/ml, InvivoGen), N-acetyl-L-cysteine (1 mM,
Sigma) Wnt3a-conditioned medium (50% v/v, L-WNT3A cell line is available from
ATCC), RSPO1-conditioned medium (20% v/v, the cells were kindly provided by
Calvin Kuo. A cell line is also available from Trevigen.), recombinant Noggin
protein (0.1 μg/ml, Peprotech), epidermal growth factor (EGF, 50 ng/ml,
Peprotech), ﬁbroblast growth factor 10 (FGF10, 100 ng/ml, Peprotech),
Nicotinamide (10 mM, Sigma), SB202190 (10 μM, Stem Cell Technologies), and
A83-01 (0.5 μM, Tocris).
Organoid culture. Organoid culture medium was refreshed every 2 days. To
passage the organoids, BME-2 was disassociated by pipetting. The organoids were
collected in a falcon tube and TrypLE (Invitrogen) added before being incubated at
37 °C for approximately 5 min. A vigorous manual shake would ensue before the
suspension was centrifuged at 300–400×g for 2 min. The remaining cell pellet was
re-suspended in 7.5 mg/ml BME-2 supplemented with complete media and plated
as 10–15 μl droplets in a 6-well plate. After allowing the BME-2 to polymerize,
complete media was added and the cells left at 37 °C.
Whole-genome sequencing. Snap-frozen tissues and blood samples were pre-
pared for whole-genome sequencing as part of the OCCAMS Consortium ICGC
project by Illumina. Paired-end sequencing (100 bp) was performed to a depth of
50× for tumors and 30× for DNA derived from normal squamous esophageal tissue
or blood samples. The analysis demonstrated that 94% of the genome was
sequenced to at least 8× coverage while achieving a PHRED quality of at least 30
for at least 80% of mapping bases. QC metrics were computed on a per-lane basis
using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and in-
house tools, enabling the identiﬁcation of sequence reads that required trimming.
DNA extracted from snap-frozen organoid cell pellets was prepared for whole-
genome sequencing. Paired-end sequencing (150 bp) was conducted on the Illu-
mina HiSeqX platform at a depth of 30×.
RNA sequencing. RNA-sequencing of organoids was performed using Illumina
TruSeq Stranded mRNA LT Sample Prep Kit Set A and Set B. mRNA was
puriﬁed using Oligo dT attached magnetic beads and then fragmented using
divalent cations. The mRNA fragments were copied into ﬁrst strand cDNA
using random hexamer primers and reverse transcriptase. Second strand
synthesis employed DNA polymerase I and RNase H. cDNA fragments
underwent end-repair, the addition of a single A base and ligation of indexed
adapters. Products were puriﬁed and enriched by PCR using Kapa HiFi polymerase
prior to quantiﬁcation and pooling prior to sequencing on an Illumina HiSeq 4000
instrument at 75 bp PE.
Whole-genome sequencing analysis. Read sequences were mapped to the
human reference genome (GRCh37) using Burrows-Wheeler Alignment (BWA)
0.5.935. Duplicates were marked and discarded using Picard 1.105 (http://
broadinstitute.github.io/picard). The data underwent an extensive quality
assurance process, and quality control metrics and alignment statistics were
computed on a per-lane basis. The FastQC package was used to assess the quality
score distribution of the sequencing reads and perform trimming if necessary.
Somatic mutations and InDels were called using Strelka 1.0.1336 and subsequent
ﬁltering was applied as described in ref.13 including Dis-
tanceToAlignmentEndMedia, DistanceToAlignmentEndMAD, LowMapQual,
MapQualDiffMedian, VariantMapQualMedian, VariantBaseQualMedian,
VariantAlleleCount, VariantAlleleCountControl, StrandBias, Repeat,
SNVCluster50, SNVCluster 100). The resulting variants were functionally
annotated using Variant Effect Predictor (VEP release 75). In order to aid the
detection of variants called in the organoids and missed in the tumor due to
allele frequency below the imposed cut-offs (as a result of low purity/subclonal
selection) in an automated manner, we combined the BAM ﬁles from the tumor
and patient-matched organoid culture, and recalled the SNVs and InDels using
Strelka on the combined resulting reads with the same ﬁltering cut-offs. This
step had the effect of increasing the read count and conﬁdence of calling real
variants for the ones that differed between tumor and organoid. Key driver
genes were also manually inspected to conﬁrm the pooled call results.
In addition, we calculated allele counts from the BAM ﬁles for tumor, organoid,
and pooled samples at all positions where a variant was called in any sample for
the case. For the pooled BAM ﬁles, allele frequencies at some positions were
raised above the threshold for consideration by Strelka, and overall the number of
variants called by Strelka and passing GATK ﬁlters was increased compared
with the individual BAM ﬁles. For each case, variants that were called from the
pooled BAM ﬁle, but only called in the tumor or the organoid(s), are considered
as present in both the tumor and the organoid(s) if the variant allele is
represented in the tumor BAM ﬁle and the organoid BAM ﬁle(s). Such variants in
key driver genes were manually inspected using the IGV tool, to conﬁrm the
concordance between the tumor and the organoid(s).
Copy number segmentation was performed using ASCAT-NGS v2.137, using
read counts at germline heterozygous positions estimated by GATK 3.2-238. Cut-
offs for copy number changes were deﬁned based on the segmental copy
number relative to the average ploidy ps in the sample as follows: ampliﬁcation:
≥2 × ps; gain: >1.25 × ps; loss: <0.75 × ps, deletion: copy number 0. For selected
key genes in pathways downstream of RTKs, the average copy number across
all genes in the respective family was calculated (e.g., RAS would summarize
the copy number landscape of HRAS, KRAS, and NRAS) and subsequently
mapped according to the deﬁned cut-offs. Structural variants were called using
Manta39. SVs were ﬁltered against a panel of matched tissue normals. We then
ﬁltered out structural variant calls overlapping problematic regions such as
gaps, satellite sequences, simple repeats >1000 base pairs and extreme read
depth regions. We also discarded deletions <1000 base pairs not supported by at
least one read, and inversions of <10 kb which are likely to be artefactual.
Exposures to the six EAC signatures described in previous study13 were inferred
using a quadratic programming approach that models the mutational counts in
each genome based on the pre-deﬁned mutational probabilities of these signatures,
as detailed in ref.13. Subsequent assignment of organoids to one of the three
mutational signature subtypes was performed based on the most prevalent
individual signature contribution in the respective genome, with the exception
of S17A and S17B where a summed contribution counted toward assignment to
the “mutagenic” signature.
RNA-seq analysis. Gene expression was quantiﬁed using Salmon40 in
quasi-mapping mode and with parameters −l= ISR and −p= 10. The Ensembl
gene annotation GRCh37.87 was provided. Transcript expression was
collapsed to gene-level expression in R using tximport41 and providing the
transcript-to-gene mapping from the Ensembl gene annotation. Genes with
zero counts in all samples were excluded from the analysis. Read counts were
normalized and log2-transformed using variance stabilization (vst) as implemented
in DESeq242 setting blind= FALSE and taking into account the sample class,
which here indicates whether the sample is a tumor, normal squamous esophagus,
or organoid.
For quantifying the expression of SNVS, RNA-seq reads were mapped to
the GRCh37_g1k genome assembly using STAR43. Following GATK’s38 best
practice on ‘Calling variants in RNAseq’, readgroups were added and duplicates
marked using Picard44. GATK’s SplitNCigarReads for trimming reads and
assigning mapping qualities was applied. The sets of SNVs identiﬁed using
Strelka on WGS data for all tumor or organoid were merged using vcftools45.
Reads overlapping any SNV were counted using the ReadCountWalker in gatk-
tools38. Mutations were called expressed if the read depth was larger or equal 4
and the variant allele frequency was larger than 0. Supplementary Fig. 3a shows
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the fraction of expressed mutations in expressed loci where an SNV was detected in
the WGS analysis. The tumor sample for CAM412 showed much fewer expressed
mutations than other samples and variant allele frequencies were low
(Supplementary Fig. 3c).
Normalized read counts per gene were used to cluster samples using
hierarchical clustering with complete linkage and Euclidean distance. The distance
matrix and the clustering was visualized as a heatmap using pheatmap. The
clustering indicated that for CAM412 the tumor sample showed an expression
pattern more similar to normal samples than to other tumors, and the normal
sample showed comparably little similarity to other normals. Together with the
observation of few mutations being expressed in the tumor sample, we excluded
CAM412 from further analysis due to quality issues.
A detailed comparison of the expression patterns of primary tumor and
organoids was performed to see if the organoid resembles the expression proﬁle of
the tumor. There are several factors that can confound this analysis. For
example, patient samples are a mixture of cancer cells and cells from adjacent
tissue, immune cell, or stroma, which are not present in the organoids. Further,
organoids are exposed to an artiﬁcial environment that is different from the
primary tissue. To cope with these effects, the set of genes that were used to
compare tumor and organoid samples were preselected as follows. First, only
genes that are differentially expressed between normal and tumor samples and
that are less expressed in normals (p ≤ 0.01, log2-FoldChange ≤−1) compared to
tumors were selected. Second, genes that are generally differentially expressed
between tumors and organoids (p ≤ 0.01, abs(log2-FoldChange) ≥1) are thought
to be the effects of the different environment that organoids are exposed to and
were discarded. Finally, for each patient, the genes that are speciﬁcally up- or
downregulated in each patient’s organoid (1 vs. all comparison, p ≤ 0.05 and abs
(log2-FoldChange) ≤ 1) and that are among the top-50 genes with highest base
mean expression were selected.
Immunohistochemistry. Parafﬁn embedded sections of 3.5 μm were stained by a
Bond Max autostainer according to the manufacturer’s instruction (Leica Micro-
systems). Primary antibodies cytokeratin (AE1/AE3, 1:100, Dako), Vimentin
(D21H3, 1:100, Cell Signaling Technology), and p53 (D07, 1:50, Leica) were
optimized and applied with negative controls.
Immunoﬂuorescence. Brieﬂy, organoids were ﬁxed with 4% PFA, permeabilized
in Triton X-100, quenched with glycine-PBS and then incubated with primary
antibody of integrin α6 (1:100, BioLegend) overnight. Organoids were washed and
incubated with appropriate secondary antibody along with Phalloidin (Thermo
Fisher). Nuclei was stained by Hoechst (Thermo Fisher). Organoids were imaged
by confocal microscope TCS SP5 (Leica), Z stacks were taken at 1-μm intervals
through organoids, and images were processed by Volocity image analyze software
(Perkin Elmer, version 6.3.0).
Chromosome harvest and multiplex-FISH karyotyping. Cultures were incubated
for 3 h with 0.1 μg/ml Karyomax Colcemid (Gibco) before being harvested and
dissociated using TrypLE (Gibco). Cells were incubated with buffered hyptonic
solution (0.4% KCL in 10 MM HEPES) for 8–12 min at 37 °C. The cells were then
ﬁxed and washed in a 6:1 (v/v) methanol:glacial ﬁxatives and stored at −20 °C until
use. Harvesting of chromosomes and multiplex-FISH karyotyping was conducted
as previously described46.
The organoid cultures were incubated for 3 h with 0.1 μg/ml Karyomax
Colcemid (Gibco) before being harvested and dissociated using TrypLE (Gibco).
Cells were incubated with buffered hypotonic solution (0.4% KCl in 10 MM
HEPES) for 8–12 min at 37 °C. The cells were then ﬁxed and washed in a 6:1 (v/v)
methanol:glacial ﬁxative and stored at −20 °C until use.
For multiplex-ﬂuorescence in situ hybridization (M-FISH), chromosome-
speciﬁc DNA libraries were generated from 5000 copies of ﬂow-sorted
chromosomes, using GenomePlex Whole Genome Ampliﬁcation (WGA2) kit
(Sigma-Aldrich). Human 24-color painting probe was made following the
pooling strategy47. Five human chromosome pools were labeled with ATTO 425-,
ATTO 488-, CY3-, CY5-, and Texas Red-dUTPs (Jena Bioscience), respectively,
using WGA 3 re-ampliﬁcation kit (Sigma-Aldrich) and home-made dNTP
mixtures optimized for the incorporation of the aforementioned labeled dUTPs
by Taq polymerase. The labeled products were pooled and sonicated to achieve
a size range of 200–1000 bp, optimal for chromosome painting. The sonicated
DNA sample was precipitated with ethanol together with human Cot-1 DNA
(Invitrogen) and resuspended in a hybridization buffer (50% formamide, 2× SSC,
10% dextran sulfate, 0.5 M phosphate buffer, 1× Denhardt’s solution [pH 7.4]).
Metaphase preparations were dropped onto precleaned microscopic slides,
followed by ﬁxation in acetone (Sigma-Aldrich) for 10 min and dehydration
through an ethanol series (70%, 90%, and 100%). Metaphase spreads on slides
were denatured by immersion in an alkaline denaturation solution (0.5 M
NaOH, 1.0 M NaCl) for 7–8 min, followed by rinsing in 1M Tris-HCl (pH 7.4)
solution for 3 min, 1× PBS for 3 min, and dehydration through a 70%, 90%, and
100% ethanol series. The M-FISH probe was denatured at 65 °C for 10 min
before being applied onto the denatured slides. The hybridization area was
sealed with a 22 × 22-mm coverslip and rubber cement. Hybridization was
carried out in a 37 °C incubator for two nights. The post-hybridization washes
included a 5-min stringent wash in 0.5× SSC at 75 °C, followed by a 5-min rinse in
2× SSC containing 0.05% Tween20 (VWR) and a 2-min rinse in 1× PBS, both at
room temperature. Finally, slides were mounted with SlowFade Gold mounting
solution containing 4′6-diamidino-2-phenylindole (Invitrogen). Images were
visualized on a Zeiss AxioImager D1 ﬂuorescent microscope equipped with narrow
band-pass ﬁlters for DAPI, DEAC, FITC, CY3, TEXAS RED, and CY5 ﬂuorescence
and an ORCA-EA CCD camera (Hamamatsu). M-FISH digital images were
captured using the SmartCapture software (Digital Scientiﬁc UK) and processed
using the SmartType Karyotyper software (Digital Scientiﬁc UK). Approximately
20 metaphase chromosomes from each organoid culture were fully karyotyped
based on M-FISH classiﬁcation.
Clonality analysis. Analysis of clonal dynamics was carried out on four tumors
(CAM277, CAM296, CAM338, and CAM401). For each primary tumor and
each derived organoid, copy number aberrations, tumor ploidy, and purity were
called using the Battenberg algorithm48. Brieﬂy, the algorithm phases
heterozygous SNPs with use of the 1000 genomes genotypes as a reference panel.
The resulting haplotypes are corrected for occasional errors in phasing in regions
with low linkage disequilibrium. After segmentation of the resulting b-allele
frequency (BAF) values, t-tests are performed on the BAFs of each copy number
segment to identify whether they correspond to the value resulting from a fully
clonal copy number change. If not, the copy number segment is represented as a
mixture of two different copy number states, with the fraction of cells bearing each
copy number state estimated from the average BAF of the heterozygous SNPs in
that segment.
As expected, all organoids had purities estimated by Battenberg of 99–100%,
while primary tumors had estimated purities ranging between 33% and 78%.
Mutations were clustered to identify subclones, using a previously described
Bayesian Dirichlet process49. The fraction of cancerous cells represented by each
subclone, or ‘cancer cell fraction’ (CCF) in each sample (tumor or organoid) was
estimated as the median of the posterior CCF obtained from the Dirichlet process.
Quality control of subclonal clusters was performed to ﬁlter out clusters that
may result from artefacts in mutation or copy number calling, using three metrics:
(1) Clusters containing fewer than 1% of all mutations identiﬁed within a tumor;
(2) Clusters for which the median CCF of the mutations assigned to that cluster
differed by more than 0.2 from the CCF output from the Dirichlet process
clustering, in one or more samples; (3) Clusters in which more than 50% mutations
occurred on the same chromosome. The previously described ‘sum’ and ‘crossing’
rules50 were used to determine whether subclones should be nested or disjoint in
Fig. 5 and Supplementary Fig. 4.
Drug screening assays. Thirty-two microliters of an organoid suspension were
dispensed into all wells of a 384-well plate containing 8 μl of 7.5 mg/ml BME-2, for
a total assay volume of 40 μl. A 7-point half-log dilution series of each
compound was dispensed using liquid handling robotics the following day and
cell viability assayed using CellTiter-Glo® (Promega) following 6 days of drug
incubation22,30. Screens were performed in technical duplicate and for 6 of the 9
organoids biological replicates were generated. AUC and IC50 values are the
mean across all replicates. All screening plates were subjected to a manual
inspection of data and a Z-factor score comparing negative and positive control
wells calculated (median= 0.58; range (0.1–0.87). Dose–response curves were ﬁtted
to the luminescent signal51. Compound and screening concentrations are provided
in Supplementary Data 3.
Proﬁling of the organoid models to the chemotherapy agents was
conducted similar to that described above. The drug combinations were
conducted using an anchored approach, whereby cisplatin and 5-ﬂuorouracil
were kept constant at a single concentration of 4 μM and 10 μM, respectively, while
a 7-point half-log dilution series of epirubicin (maximum concentration 10 μM)
was used.
Data availability. The RNA and whole-genome DNA sequencing data are avail-
able at the European Genome-phenome Archive (EGA) under accession
EGAD00001004007. Information to match the sample identiﬁer to the patients and
organoids is provided in Supplementary Table 3.
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